Figures in this article are as of July 2026 and are general information, not tax, legal, or regulatory advice. Tax and regulatory rules change; sponsors should confirm current requirements with qualified advisers.
Australia’s entire pitch to early-phase sponsors rests on a single, genuinely attractive lever: the Research & Development Tax Incentive (R&DTI). For companies with aggregated turnover under A$20M, it delivers a 43.5% refundable tax offset on eligible R&D spend, and clinical-trial expenditure is exempt from the standard A$4M annual refund cap. Those figures are in force for FY2025–26 and FY2026–27.
It’s financing, not a discount
The most common mistake is treating a 43.5% rebate as if it were a 43.5% price cut. It isn’t. To claim the offset, the R&D generally has to be conducted by an eligible Australian company — so most U.S. startups incorporate an Australian subsidiary, register the activities with AusIndustry, and engage local tax and legal advisers to lodge and defend the claim. And the cash arrives only after the Australian year-end tax lodgement: you spend the full gross cost now and recover part of it later. A market of rebate-advance lenders exists to bridge the gap, but that financing has a cost of its own.
Two qualifiers matter. First, the threshold is aggregated turnover, which counts connected entities and affiliates — including a U.S. parent. Second, a redesign of the program has been announced/proposed (not yet legislated) that would change eligibility from 1 July 2028 — raising the refundable-offset turnover threshold to A$50M while limiting refundability to companies under 10 years old; current-year claims are unaffected.
The gross-cost math
Because the sponsor funds the gross cost regardless, the honest comparison is on a gross, cash-contracting basis — the number that actually hits the runway — with the rebate treated as a separate, conditional recovery. On that basis, in bioaccess®’s program experience:
| Basis of comparison | Latin America vs Australia |
|---|---|
| Gross (cash) cost | ~35–45% lower in Latin America |
| After a fully-captured Australian rebate | Effective gap narrows to ~5–15%; in some programs the rebate can close or reverse it |
| Entity required to access the rebate | Australia: yes (eligible entity < A$20M aggregated turnover). Latin America: none |
| When the money moves | Australia: fund gross now, recover part after year-end lodgement. Latin America: pay for work as delivered |
Actual deltas vary with trial design, exchange rates, and how much of the rebate is ultimately captured — which is exactly why we compare on gross and let each sponsor model the rebate against their own eligibility.
Speed is roughly a wash
Australia is often assumed to be faster to start. In practice, end-to-end start-up is broadly comparable once you include Australian site governance. Australia’s Clinical Trial Notification (CTN) route requires no TGA pre-review, but it typically involves ~6–8 weeks of Human Research Ethics Committee (HREC) review plus separate, site-by-site research-governance approvals. In Latin America, Argentina’s ANMAT review is capped by Disposition 7516/2025 (Annex III) at ~35 technical + 10 administrative business days (≈45) for Phase I / non-low-risk studies — ~30 for low-risk — with ethics in parallel and a 2-day admission check (queries pause the clock). Speed is not the reason to choose Australia — the rebate is.
The frictions that erode the rebate
For a U.S. team, several practical variables push against Australia and are easy to leave out of a headline rebate calculation:
- Distance and time zone: ~14–20+ hours of travel and a 14–18 hour time difference make weekly oversight of a first-in-human study genuinely hard.
- Per-patient site cost: below U.S./EU, but generally above Latin American site costs.
- Recruitment: a smaller population base and site-level competition for participants can slow enrollment.
- The entity overhead itself: standing up and running an Australian subsidiary is real cost and management attention for a 3–5 person team.
Latin America keeps the study close to your time zone with short-haul travel, a lower cash-basis cost, no foreign entity to establish, and the same regional infrastructure that carries your later patient-phase work.
FDA acceptance is geography-neutral
A frequent worry is that U.S. regulators favor Australian data. They don’t. Foreign clinical data from either region can support a U.S. submission when it meets the applicable requirements — 21 CFR 812.28 for devices and 21 CFR 312.120 for drugs, conducted under GCP (ISO 14155 for devices; ICH E6 for drugs). Acceptance is an FDA determination made case-by-case, subject to the agency’s data-validation and supporting-information requirements — not a function of the country of origin. The same holds for ethnic-bridging questions at agencies like Japan’s PMDA: data applicability is assessed case-by-case, and it does not turn on whether the trial ran in Latin America, Australia, or Canada.
Where Australia genuinely wins
An honest comparison concedes the other side’s strengths, and Australia has real ones: arguably the longest early-phase-to-global-pivotal track record for many modalities; English-language operations end-to-end; gold-standard healthy-volunteer units and among the most automated PK-lab infrastructure; and a hard-to-beat rebate if you can and will structure an eligible Australian entity. If those factors are central to your program — or if an Australian R&D footprint is something your investors specifically want — Australia may be the right call.
The honest bottom line
Treat Australia as the comparator a board will expect, not the default. For most lean, U.S.-focused device and early-phase teams, Latin America reaches human data faster on a total-cost-and-time basis — and cheaper on a gross, cash basis even before the rebate — without standing up a foreign subsidiary.
One U.S. medical-device startup came to bioaccess® after an Australian ethics committee declined its first-in-human study. Ethics committees decline studies for many reasons — local feasibility, insurance, standard-of-care fit — not only safety. After the sponsor changed course to Latin America, the program is moving forward, with clinical sites now being activated in El Salvador and Panama and Chile under evaluation.
Want the row-by-row version? See the bioaccess® vs Australia comparison, or estimate your own path with the FIH Launch Planner.
Frequently asked questions
Is Australia’s R&D tax incentive worth it for a small medtech or biotech startup?
It can be — but weigh the whole picture. The 43.5% refundable offset is real for groups under A$20M aggregated turnover, and clinical-trial spend qualifies. To claim it, though, the R&D generally has to run through an eligible Australian company, and the cash only arrives after year-end lodgement, so you fund the full gross cost first. In bioaccess®’s program experience the gross, cash cost in Latin America runs about 35–45% below Australia, and the rebate narrows that to roughly 5–15% only when fully captured. This is general information, not tax advice.
Australia vs Latin America — which is cheaper?
On a gross, cash-contracting basis, Latin America is, in bioaccess®’s program experience, about 35–45% below Australia. Australia’s rebate can recover ~43.5% of eligible spend, narrowing the effective gap to roughly 5–15% and in some programs closing or reversing it — but only with an eligible Australian entity, funding the gross while awaiting the refund.
Will the FDA accept data from a Latin American trial like it would from an Australian one?
Yes — foreign clinical data from either region can support a U.S. submission when it meets 21 CFR 812.28 (devices) or 312.120 (drugs), conducted under GCP. Acceptance is determined case-by-case, subject to FDA’s data-validation and supporting-information requirements, not by the country of origin.
bioaccess® is the First-in-Human CRO — U.S. regulatory anchoring plus Latin American execution for MedTech, Biopharma, and Radiopharma startups.